Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The verification of wildland-urban interface fire evacuation models.
Ronchi E, Wahlqvist J, Ardinge A, Rohaert A, Gwynne SMV, Rein G, Mitchell H, Kalogeropoulos N, Kinateder M, Bénichou N, Kuligowski E, Kimball A. Ronchi E, et al. Among authors: gwynne smv. Nat Hazards (Dordr). 2023;117(2):1493-1519. doi: 10.1007/s11069-023-05913-2. Epub 2023 Mar 28. Nat Hazards (Dordr). 2023. PMID: 37251348 Free PMC article.
Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial.
Mukherjee S, Hurt CN, Adams R, Bateman A, Bradley KM, Bridges S, Falk S, Griffiths G, Gwynne S, Jones CM, Markham PJ, Maughan T, Nixon LS, Radhakrishna G, Roy R, Schoenbuchner S, Sheikh H, Spezi E, Hawkins M, Crosby TDL. Mukherjee S, et al. Among authors: gwynne s. EClinicalMedicine. 2023 Jun 26;61:102059. doi: 10.1016/j.eclinm.2023.102059. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37409323 Free PMC article.
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J, Al-Mukhtar A, Dickson E, Graham J, Jiao L, Wasan HS, Tait IS, Prachalias A, Ross P, Valle JW, O'Reilly DA, Al-Sarireh B, Gwynne S, Ahmed I, Connolly K, Yim KL, Cunningham D, Armstrong T, Archer C, Roberts K, Ma YT, Springfeld C, Tjaden C, Hackert T, Büchler MW, Neoptolemos JP; European Study Group for Pancreatic Cancer. Ghaneh P, et al. Among authors: gwynne s. Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12. Lancet Gastroenterol Hepatol. 2023. PMID: 36521500 Free article. Clinical Trial.
SCOPE 2 - Still Answering the Unanswered Questions in Oesophageal Radiotherapy? SCOPE 2: a Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients with Oesophageal Cancer Treated with Definitive Chemoradiation with an Embedded Phase II Trial for Patients with a Poor Early Response using Positron Emission Tomography/Computed Tomography.
Bridges S, Thomas B, Radhakrishna G, Hawkins M, Holborow A, Hurt C, Mukherjee S, Nixon L, Crosby T, Gwynne S. Bridges S, et al. Among authors: gwynne s. Clin Oncol (R Coll Radiol). 2022 Jul;34(7):e269-e280. doi: 10.1016/j.clon.2022.03.019. Epub 2022 Apr 21. Clin Oncol (R Coll Radiol). 2022. PMID: 35466013 Clinical Trial.
45 results